16 November 2021 | News
insigHT2021, a three-day international conference exemplifies post pandemic recovery strategies to forge resilience for the global healthcare travel industry
insigHT2021, Malaysia's medical travel market intelligence conference, featured the launch of Malaysia as the Hepatitis C Treatment Hub of Asia by Minister of Health Malaysia, Yang Berhormat Khairy Jamaluddin.
Being the first country in the world to be given conditional approval for Ravidasvir in combination with Sofosbuvir to treat Hepatitis C, Malaysia is poised to offer access to an affordable and efficacious treatment solution for those infected with the virus.
“In response to the World Hepatitis Day 2021 theme, “Hepatitis Can’t Wait”, Malaysia is ready and raring to move forward with a treatment solution for those infected with the disease. This is in line with WHO’s mission to reduce new viral hepatitis infections by 90% and reduce deaths by viral hepatitis by 65% by 2030. Malaysia is offering Hepatitis C patients a treatment with a cure rate of 97% and cost reduction of 95%,” said YB Khairy Jamaluddin, Minister of Health Malaysia at the insigHT2021 opening ceremony.
insigHT2021 is hosted virtually from 16 to 18 November and is anchored by Malaysia Healthcare Travel Council (MHTC), an agency under the Ministry of Health tasked to facilitate and promote the healthcare travel industry in Malaysia.
Carrying the theme ‘Forging Resilience’, the conference features insights on post-pandemic recovery strategies and opportunities for industry resilience with topics such as reimaging the health system, the future of healthcare and well-being, and rebuilding hospitality delivered by renowned local and international industry experts.
Image caption- L-R- YB Khairy Jamaluddin- Minister of Health Malaysia, Mohd Daud Mohd Arif-Chief Executive Officer, MHTC, YBhg. Tan Sri Dato' Seri Dr. Noor Hisham Abdulah- Director General, Ministry of Health Malaysia at the launch of Malaysia as the Hepatitis C Treatment Hub of Asia.